1 Circulating anti-Müllerian hormone levels in pre-menopausal women: novel genetic 2 insights from a GWAS meta-analysis

- 3 Natàlia Pujol-Gualdo#(1,2), Minna K. Karjalainen (3,4), Urmo Võsa (1), Riikka K. Arffman (2),
- 4 Reedik Mägi (1), Justiina Ronkainen(3), Triin Laisk*(1), Terhi T. Piltonen*(2)
- 5 #first and corresponding author / *co-last authorship
- 6 1. Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
- 2. Department of Obstetrics and Gynecology, Research Unit of Clinical Medicine, Universityof Oulu, Oulu, Finland
- 9 3. Research Unit of Population Health, Faculty of Medicine, University of Oulu, Oulu, Finland
- 10 4. Northern Finland Birth Cohorts, Arctic Biobank, Infrastructure for Population Studies,
- 11 Faculty of Medicine, University of Oulu, Oulu, Finland

12 Abstract

Study question: Can a genome-wide association study (GWAS) meta-analysis, including a large sample of young premenopausal women from a founder population from Northern Finland, identify novel genetic variants for circulating anti-Müllerian hormone (AMH) levels and provide insights into biological pathways and tissues involved in AMH regulation?

Summary answer: We identified six loci associated with AMH levels at $P < 5 \times 10^{-8}$, including the previously reported *MCM8*, *AMH* and *TEX41* loci, and three novel signals in or near *CHEK2*, *BMP4* and *EIF4EBP1*. Gene set enrichment analysis highlighted significant enrichment in renal system vasculature morphogenesis and tissue enrichment analysis ranks the pituitary gland as a top associated tissue.

What is known already: AMH is expressed by preantral and small antral stage ovarian follicles in women, and variation in age-specific circulating AMH levels has been associated with several health conditions. However, the biological mechanisms underlying the association between health conditions and AMH levels are not yet fully understood. Previous GWAS have identified loci associated with AMH levels in pre-menopausal women, but they were limited by small sample sizes or focused mostly on older pre-menopausal women.

Study design, size, duration: We performed a GWAS meta-analysis for AMH level measurements in 9,668 pre-menopausal women.

Participants/materials, setting, methods: We performed a GWAS meta-analysis in which
 we combined 2,619 AMH measurements (at age 31 years old) from a prospective founder
 population cohort (Northern Finland Birth Cohort 1966, NFBC1966) with a previous GWAS
 meta-analysis that included 7,049 pre-menopausal women (spanning age range 15-48).
 NFBC1966 AMH measurements were quantified using an automated assay (Elecsys® AMH
 Plus (Roche)). We annotated the genetic variants, combined different data layers to prioritise
 potential candidate genes, described significant pathways and tissues enriched by the

GWAS signals, identified plausible regulatory roles using colocalization analysis and
 leveraged publicly available summary statistics to assess genetic and phenotypic
 correlations with multiple traits.

40 Main results and the role of chance: Three novel genome-wide significant loci were 41 identified. One of these is in complete linkage disequilibrium with c.1100delC in CHEK2, 42 which is found to be 4-fold enriched in the Finnish population compared to other European 43 populations. We propose a plausible regulatory effect of some of the GWAS variants linked to AMH, as they colocalise with GWAS signals associated with gene expression levels of 44 45 BMP4, TEX41 and EIFBP41. Gene set analysis highlighted significant enrichment in renal system vasculature morphogenesis and tissue enrichment analysis ranked the pituitary 46 47 gland as the top association.

48 **Large scale data:** The GWAS meta-analysis summary statistics will be available for 49 download from the GWAS Catalog. Accession numbers will be provided upon publication.

Limitations, reasons for caution: This study only included women of European ancestry and the unavailability of sufficiently sized relevant tissue data in gene expression datasets hinders the assessment of potential regulatory effects in reproductive tissues.

Wider implications of the findings: Our results highlight the increased power of founder populations and larger sample sizes to boost the discovery of novel trait-associated variants underlying variation in AMH levels, which aided to characterise novel biological pathways and plausible genetic regulatory effects linked with AMH levels variation for the first time.

57 Study funding / competing interest(s): This work has received funding from the European 58 Union's Horizon 2020 research and innovation programme under the MATER Marie 59 Sklodowska-Curie grant agreement No. 813707 and Oulu university scholarship foundation (N.P.-G.), Academy of Finland, Sigrid Jusélius Foundation, Novo Nordisk, University of Oulu, 60 Roche Diagnostics (T.T.P). This work was supported by the Estonian Research Council 61 grant 1911 (R.M.). J.R. was supported by the European Union's Horizon 2020 research and 62 innovation program under grant agreements No. 874739 (LongITools), 824989 (EUCAN-63 Connect), 848158 (EarlyCause) and 733206 (LifeCycle). U.V. was supported by the 64 65 Estonian Research Council grant PRG (PRG1291). The NFBC1966 received financial support from University of Oulu Grant no. 24000692, Oulu University Hospital Grant no. 66 24301140, ERDF European Regional Development Fund Grant no. 539/2010 A31592. 67

Keywords: AMH; anti-Mullerian hormone, genome-wide association study, low-frequency
 variants, reproductive ageing

70 INTRODUCTION

Anti-Müllerian hormone (AMH) is a member of the transforming growth factor β (TGF- β) superfamily, which includes the bone morphogenic proteins (BMPs), growth differentiation factors, activins and inhibins. Despite owing its name to its classical role in male sexual differentiation, AMH is also expressed by the ovarian granulosa cells during the primary to small antral stage of follicle development (Weenen *et al.*, 2004). In adult women, serum AMH levels decrease with age, with undetectable levels following menopause, signalling depletion of ovarian reserve (Finkelstei *et al.*, 2020). As a result, AMH is primarily known as

a serum marker for ovarian reserve. Previous studies have indicated that variations in agespecific circulating AMH levels are linked with several health conditions, including breast
cancer (Ge *et al.*, 2018) and polycystic ovary syndrome (PCOS) (Homburg and Crawford,
2014). Therefore, identifying genetic determinants of inter-individual variation in AMH
measurements may offer valuable insight into their biological mechanistic effects and impact
in health and disease beyond reproductive ageing.

84 Three previous genome-wide association studies have identified a few loci associated with 85 AMH levels in pre-menopausal women (Schuh-Huerta et al., 2012; Ruth et al., 2019; 86 Verdiesen et al., 2022). However, these studies were limited by small sample size (Schuh-87 Huerta et al., 2012) or focusing only or mostly on older pre-menopausal women (Ruth et al., 2019; Verdiesen et al., 2022). Since AMH decreases with age also the AMH variability 88 decreases in older ages, and therefore there is less power to detect associations in older 89 90 pre-menopausal women compared to younger pre-menopausal women. To address these 91 limitations, our current work analyses data from a single time point measured in relatively 92 young pre-menopausal women and combines this dataset with a previous meta-analysis 93 (Verdiesen et al., 2022), to identify and characterise additional loci associated with AMH 94 levels in pre-menopausal women.

95 The studies conducted so far have focused on European ancestry, mainly powered to 96 discover associations with common genetic variants. Nonetheless, founder populations such 97 as those found in northern Finland, represent a powerful resource to accelerate discovery of 98 new biological mechanisms driven by low-frequency alleles that have risen to higher 99 frequency due to unique demographic history (Kurki *et al.*, 2023).

100 In the present study, we added 2,619 AMH measurements (at age 31 years old) from a 101 prospective founder population cohort (Northern Finland Birth Cohort 1966, NFBC1966) to a 102 previous GWAS meta-analysis of 7,049 pre-menopausal women (spanning age range 15-103 48) (Verdiesen et al., 2022), reaching the largest sample size for assessing AMH variation in women from reproductive age to date (N=9,668). Beyond detecting three out of the four 104 105 previously identified signals near TEX41, MCM8 and AMH, we identified three novel signals near EIF4EBP1, BMP4, and CHEK2. In the CHEK2 locus, the c.1100delC variant is enriched 106 107 in the Finnish population and in complete linkage disequilibrium $(r^2=1)$ with the lead variant 108 identified in that locus. Additionally, we tested regulatory effects of GWAS variants on 109 specific genes and gene transcript expression in multiple tissues using colocalization 110 analysis, evaluated gene set and tissue set enrichments, and estimated genetic correlations 111 and phenotypic associations across multiple phenotypes, by leveraging publicly available 112 summary statistics.

113 METHODS

114 Study design and setting

115

116 This study is based on the prospective population-based NFBC1966 study (University of Oulu, 1966, http://urn.fi/urn.nbn:fi:att:bc1e5408-980e-4a62-b899-43bec3755243). During 117 118 1966, 12231 children (of them 5,889 females) were born in the two northernmost provinces 119 of Finland (covering 48% of Finnish territory). Originally, the study was set to evaluate early 120 life factors on long-term health and work ability. The cohort population has been followed up 121 at four different time points: 1, 14, 31 and 46 years of age (set by the cohort centre). 122 Comprehensive guestionnaires on female health and clinical examinations with biological 123 data collection were performed at ages 31 and 46 years.

The detailed cohort description and follow up protocol has been previously published (Nordström *et al.*, 2022). Briefly, in 1997 (the 31-year follow-up) women living in the Northern Finland area or in the Helsinki metropolitan area (n=4074 women) were invited to a clinical examination, in which 3,127 (77%) women participated. The present study includes 2,619 women with AMH and genetic data available at 31 years old (median=31.1, interquartile range (IQR)=30.9-31.4).

131 132 For the meta-analysis, publicly available summary statistics from an independent second 133 study evaluating AMH variations across 7,049 pre-menopausal women were used 134 (Verdiesen et al., 2022). Publicly available summary statistics were downloaded from the GWAS catalog (https://www.ebi.ac.uk/gwas/publications/35274129) under accession 135 136 number GCST90104596. This study included data from the AMH GWAS meta-analysis by 137 Ruth et al. (n=3,334) (Ruth et al., 2019), which meta-analysed four studies, and three 138 cohorts which were additionally analysed and joined to the latter, conforming the most recent 139 meta-analysis (n=7,049) (Verdiesen et al., 2022). The cohort details from the current meta-140 analysis (n=9,668) can be found in Supplementary Table 1. More details of cohort 141 description of the studies included can be found in (Verdiesen et al., 2022). All studies had 142 received ethical approval from institutional ethics committees.

143 144

145 AMH measurement in NFBC1966

Serum samples were drawn in 1997 (the 31-year follow up), sealed and stored at -20°C
since then. Serum AMH concentrations were measured using the automated Elecsys®
electrochemiluminescence immunoassay on a Cobas E411 analyser according to the
manufacturer's instructions (Roche Diagnostics, Germany). More detailed information on
AMH measurement has been published previously (Piltonen *et al.*, 2023).

151 The assay limits of detection and quantitation were 0.01 ng/ml and 0.03 ng/ml for AMH. 152 Intra- and inter-assay coefficients of variance were 1.0–1.8% and 2.9–4.4% for AMH. Limits 153 above the measuring ranges were 23 ng/ml for AMH.

AMH concentrations were converted to pmol/l using 1 ng/ml = 7.14 pmol/l. As AMH levels are not normally distributed, for the following analysis AMH measurements were transformed using rank-based inverse normal transformation, as done previously (Ruth *et al.*, 2019). For rank-based inverse normal transformation we used the package *RNOmni* in R v3.6.3.

158 Genotyping details and association analysis

159 Genotyping of the NFBC1966 samples was performed with the Illumina Infinium

HumanCNV370-Duo array. Samples were excluded based on call rate < 95%, gender mismatch, relatedness (identity by descent (IBD) estimate pihat>0.2) and outlying heterozygosity. SNPs were excluded based on missingness rate >5%, HWE p <0.000001 and MAF <1%. Genotypes were imputed with Beagle 4.1 using the SiSu v3 imputation reference panel, which consisted of 3775 individuals of Finnish ancestry with sequenced whole genomes.

166

Association analysis was performed using SNPTEST v2.5.4-beta1, adjusted by the first 10 genetic principal components. Markers with INFO score >0.4 were kept for the metaanalysis. Positions were converted to build hg37 to harmonise the data with the summary

statistics available from Verdiesen *et al.* before running the meta-analysis, using LiftOver
 (Kent *et al.*, 2002).

172

173 GWAS meta-analysis

We conducted an inverse variance weighted fixed-effects meta-analysis with single genomic control correction using GWAMA software (v2.2.2) (Mägi and Morris, 2010). A total of 13,903,812 variants were included in the meta-analysis of 9,688 AMH measurements. After meta-analysis we kept variants present in both studies (totalling 7,900,839 variants) for downstream analysis. Lead SNPs were identified as SNVs independent from each other with *P*-value less than or equal to $5 \square x \square 10^{-8}$. The maximum distance between LD blocks of independent SNPs to merge into a single genomic locus was set to $500 \square kb$.

181 Heritability analysis

182 The heritability (h²) was estimated by single-trait LD score regression using the meta-183 analysis summary statistics and HapMap 3 LD-scores using LDSC v1.0.1 184 (<u>https://github.com/bulik/ldsc</u>) (Bulik-Sullivan *et al.*, 2015).

185 Annotation of GWAS signals

We used FUMA (v1.4.0) to annotate the GWAS signals (Watanabe et al., 2017). FUMA is an 186 187 online platform that performs annotation of GWAS signals using data from several 188 databases. First, FUMA identifies lead SNPs (p-value <=5 x 10⁻⁸ and SNP pairwise LD 189 r2<0.1, based on 1000G European reference) and independent significant SNPs and each 190 risk locus (p-value <5 \times 10⁻⁸ and LD r2< 0.6) (Supplementary Table 2). Then FUMA 191 identifies potential candidate SNPs that are in LD with any of the identified independent 192 significant SNPs and annotates them via linking with several databases (ANNOVAR, 193 RegulomeDB, CADD scores etc.), which gives information on their location, functional 194 impact, and potential regulatory effects.

195 196

197 Colocalization analysis198

We used HyPrColoc (Foley *et al.*, 2021), a colocalisation method for identifying the overlap between our GWAS meta-analysis signals and cis-quantitative trait loci (cis-QTL) signals from different tissues and cell types (expression QTLs, transcript QTLs, exon QTLs and exon usage QTLs available in the eQTL Catalogue (Kerimov *et al.*, 2021)). We lifted the GWAS summary statistics over to hg38 build to match the eQTL Catalogue using binary liftOver tool (https://genome.sph.umich.edu/wiki/LiftOver#Binary_liftOver_tool).

For the genome-wide significant ($p <= 5 \times 10^{-8}$) GWAS loci identified we extracted the +/-205 206 500kb of its top hit from QTL datasets and ran the colocalization analysis against eQTL 207 Catalogue traits. For each eQTL Catalogue dataset we included all the QTL features which 208 shared at least 80% of tested variants with the variants present in our GWAS region. We 209 used the default settings for HyPrColoc analyses and did not specify any sample overlap 210 argument, because HyPrColoc paper (Foley et al., 2021) demonstrates that assuming trait 211 independence gives reasonable results. HyPrColoc outputs the posterior probability that 212 genetic association signals for those traits are colocalising (we considered two or more

signals to colocalize if the posterior probability for a shared causal variant (PP4) was 0.8 or higher). All results with a PP4 > 0.8 can be found in Supplementary Table 3.

215 Gene prioritization

In order to nominate plausible candidate genes in each locus, we prioritized genes according to different levels of evidence: (1) genes containing lead variants that are coding variants or coding variants in high LD ($r2 \square > \square 0.6$) with lead variants; (2) genes whose expression was regulated by eQTL variants that showed significant (posterior probability >0.8) colocalization with our GWAS signals; (3) genes which showed a plausible biological role as defined previously in the research literature.

222 Gene set and tissue set enrichment analysis

Gene set enrichment analysis and tissue set enrichment analysis were performed using MAGMA v1.08 implemented in FUMA v1.4.0. Gene sets were obtained from Msigcbv7.0 for 'Curated gene sets' and 'GO terms'. A total of 15,485 gene terms were queried. The results of this analysis are presented in Supplementary Table 4 and Supplementary Figure 2. Tissue expression analysis was performed for 53 tissue types using MAGMA. The results of this analysis are presented in Supplementary Table 5 and Supplementary Figure 2.

229 Genetic correlation analysis

The Complex Traits Genetics Virtual Lab (CTG-VL, <u>https://vl.genoma.io/</u>) was used to calculate genetic correlations between the AMH meta-analysis and 1335 traits. We applied a multiple testing correction (Benjamini-Hochberg FDR < 5%) to determine statistical significance using the *p.adjust* function in R 3.6.3. Results of the genetic correlation analysis are presented in Supplementary Figure 3 and Supplementary Table 6.

235

Phenome-wide associations237

We evaluated the association of our GWAS lead variants and variants in high LD with these by using human health traits and phenotypes available in the GWAS Catalog (e0_r2022-11-29) as implemented in FUMA. We also queried the lead variants of this study from the FinnGen study (data freeze 9, total n=377,277), which combines samples collected from Finnish biobanks to digital health care data (Kurki *et al.*, 2023). The results obtained are found in Supplementary Table 7 and 8 and Supplementary Figure 4.

- 244
- 245
- 246 247
- 248
- 249
- 250

251 RESULTS

252

253 Genome-wide association study for AMH levels

To detect genetic factors associated with circulating AMH levels, we performed a GWAS meta-analysis with data from two studies (NFBC1966 GWAS and summary statistics publicly

- available from Verdiesen *et al.*, 2022 including a total of 9,668 AMH measurements
 quantified from women of pre-menopausal age and European ancestry.
- 258 The meta-analysis identified a total of six associated loci, with six independent signals
- significantly associated with AMH levels ($P = = 5 \times 10^{-8}$) (Table 1, Supplementary Figure
- 1). A total of 70 SNPs reached genome-wide significance ($P = = 5 \times 10^{-8}$).



262 263

Supplementary Figure 1. Regional plots showing the six independent loci significantly associated with AMH levels. Plots were created using the LocusZoom tool 264 265 (locuszoom.org). The y axis represents -log₁₀(P-values) for association of variants with AMH

levels and the *x* axis represents the chromosomal positions of the variants. Each lead variantis shown as a purple diamond in each of the six genetic loci defined.

Table 1. Genome-wide significant signals ($p \le 5 \ge 10^{-8}$) in the meta-analysis for inverse normally transformed anti-Müllerian hormone levels in women. SNPs showing the most significant associations at each locus are shown, and novel genome-wide significant signals are highlighted in bold. EUR; European (non-Finnish), FINN: European (Finnish)

rsID (lead variant)	Chromoso me	Position (based on build 37)	Effe ct allel e	Effect allele frequenc y (EUR/FI NN)	Bet a (SE)	P- valu e	Candidat e gene	Source of support for candidate gene prioritisati on
rs6729614	2	1456448 74	G	0.26/0.25	0.08 (0.0 1)	5.56 ×10 ⁻	ZEB2/TE X41	Colocalisati on analysis and biological plausibility
rs100933 45	8	3787277 6	т	0.72/0.68	- 0.08 (0.0 1)	5.05 × 10 ⁻⁰⁹	EIF4EBP 1	Colocalisat ion analysis and biological plausibility
rs762643	14	5442276 7	т	0.44/0.41	- 0.07 (0.0 1)	3.99 × 10 ⁻⁰⁹	BMP4	Colocalisat ion analysis and biological

rs1041762 8	19	2251817	С	0.97/0.99	0.32 (0.0 4)	9.56 × 10 ⁻¹²	AMH	Coding variant and biological plausibility
rs1699161 5	20	5948227	A	0.06/0.02	0.16 (0.0 2)	4.68 × 10 ⁻⁰⁹	MCM8	Coding variant and biological plausibility
rs186430 430	22	2910359 8	С	0.002/0.0 08	0.79 (0.1 2)	9.69 × 10 ⁻¹¹	CHEK2	Frameshift variant c.1100delC in high LD with the lead variant

274

275

Three of the associated loci were previously reported and were located in or near *AMH* (rs10417628, p=9.34 × 10⁻⁰⁹), *TEX41* (rs6729614, p=1.68 × 10⁻¹⁰) and *MCM8* (rs16991615, p=4.68× 10⁻⁰⁹) (Ruth *et al.*, 2019; Verdiesen *et al.*, 2022), and three of the associated loci were novel. The novel loci included associations near *EIF4EBP1* (rs10093345, p=9.34 × 10⁻⁰⁹), *BMP4* (rs762643, p=1.98× 10⁻⁰⁹) and *CHEK2* (rs186430430, p=9.69 × 10⁻¹¹) (see Figure 1, Table 1). All lead variants were present in the two datasets analysed, and the directions of effects were consistent between the datasets for all six lead variants (Figure 2).

There was no evidence of excessive genomic inflation ($\lambda \square = \square 1.01$) in the GWAS metaanalysis (LDSC intercept= 1.0039 (s.e. 0.0076)). The observed scale SNP heritability estimate was 0.13 (s.e. 0.05).



286

292

Figure 1. Manhattan plot for GWAS meta-analysis for AMH levels in pre-menopausal women (n=9,668). The novel loci are highlighted in blue. The *y* axis represents $-\log_{10}(P$ values) for association of variants with AMH levels and the *x* axis represents the chromosomal positions of the variants. The red horizontal dashed line represents the threshold for genome-wide significance ($P = < 15 = x = 10^{-8}$).



293

Figure 2. Forest plot of effect estimates for the 6 lead variants associated with AMH levels across datasets meta-analysed. The betas and standard errors are shown for the two studies meta-analysed (NFBC1966 (green dots, n=2,619), Verdiesen *et al.* (orange dots, n=7,049), and the presented largest meta-analysis (Meta-analysis, purple dots, n=9,668). Candidate genes are also shown next to each genetic lead signal. Betas represent the effect sizes of each genetic variant association to phenotype, assessing the same risk allele across cohorts (Effect allele and effect allele frequency are reported in Table 1).

302 Characterisation of GWAS signals

Two out of the six lead variants that were detected are non-synonymous, making them notably easier to interpret and establishing a more solid foundation for pinpointing potential candidate genes. These non-synonymous variants are found in *AMH* (Anti-Mullerian Hormone) (rs10417628 in chromosome 19, p=9.56 × 10⁻¹²) and *MCM8* (Minichromosome Maintenance 8 Homologous Recombination Repair Factor) (rs16991615 in chromosome 20, p=4.68 × 10⁻⁰⁹) and were previously described to be associated with AMH levels (Ruth *et al.*, 2019; Verdiesen *et al.*, 2022).

310 In the novel locus identified on chromosome 22, the lead variant is an intronic variant near CHEK2 (Checkpoint Kinase 2) (rs186430430, p=9.69 \times 10⁻¹¹). Interestingly, this variant is in 311 312 complete linkage disequilibrium ($r^2=1$) with the frameshift variant c.1100delC in CHEK2 313 (rs555607708). Despite complete linkage disequilibrium, this rare variant is only found in the association analysis of the NFBC1966 GWAS, showing a p-value of 6.69 × 10⁻⁰⁵ and beta of 314 315 0.79 (s.e=0.12) in this cohort only and not found in the summary statistics results from 316 Verdiesen et al., likely explained by the fact that this variant is enriched in the Finnish 317 population (MAF= 0.008) compared to other European populations (MAF=0.002), and thus 318 better powered to be captured in a GWAS setting including the former population in the 319 analysis.

For the other three loci identified on chromosomes 2, 8 and 14, we defined for the first time plausible shared causal variants between GWAS signals and transcript and gene expression in specific tissues by colocalization analysis. This resulted in the prioritisation of three plausible candidate genes, respectively: *TEX41* (Testis Expressed 41), *EIF4EBP1* (Eukaryotic Translation Initiation Factor 4E Binding Protein 1) and *BMP4* (Bone Morphogenetic Protein 4) (Supplementary Table 3).

326 For instance, the association signal in chromosome 2, in an intronic region of TEX41, colocalized with eQTL signals for TEX1 transcripts ENST00000414256 in the testis 327 (PP4=0.99) and ENST00000445791 in the skin (PP4=1). EIF4EBP1 was also prioritised 328 329 based on colocalization evidence in three tissues, with high colocalization probability 330 (PP4=0.90) between the GWAS signal and cis-eQTLs for EIF4EBP1 expression in brain 331 frontal cortex tissue, and between the GWAS signal and cis-eQTLs for EIF4EBP1 332 expression in left heart ventricle. Additionally, the GWAS association signal in chromosome 333 8 showed colocalization with cis-eQTLs for BMP4 transcripts ENST00000245451 and 334 ENST00000558489 (PP4=0.84) BMP4 in colon transverse and transcript 335 ENST00000558489 in tibial nerve.

From colocalization results, only in the locus of chromosome 2, we observed that the associations might be explained by a single variant. Namely, we observed that the noncoding transcript (*TEX41*) exon variant rs17407477 and the intronic variant rs786244 were explaining most of the shared association, for the testis transcript expression association (posterior inclusion probability 0.90) and the skin transcript expression association (posterior inclusion probability 0.94), respectively.

Although we identified three out of the four signals that were previously reported in Verdiesen *et al.*, 2022, we were unable to detect the signal near *CDCA7* described in the past work (rs11683493 (T), $p=1.7 \times 10^{-8}$). In our analysis using the NFBC66 GWAS data, this variant showed a p-value of 0.09 and therefore, the resulting p-value from the metaanalysis remained below the threshold of significance ($p=1.02 \times 10^{-5}$). Although there might be various sources of variability which explains this discrepancy in our findings, we hypothesise the difference in sample size to be the primary reason.

349 Gene set and tissue set enrichment analysis

Gene set enrichment analysis highlighted significant enrichment of renal system vasculature morphogenesis ($p=5.2x10^{-8}$), glomerulus vasculature morphogenesis ($p=1.77x10^{-7}$) and glomerulus morphogenesis ($p=2.99x10^{-6}$) (see Supplementary Table 4 and Supplementary Figure 2). Tissue expression analysis yielded the strongest enrichment in the pituitary gland, even though not reaching significance after multiple testing correction ($p_{non-adj}=0.02$) (see Supplementary Figure 2 and Supplementary Table 5 and Supplementary Figure 2).



356

357

Supplementary Figure 2. Gene set and tissue set enrichment results. A) Gene set enrichment analyses with MAGMA. Green bars and the red dashed line indicate Bonferroni threshold, set to $p=0.05/15485=3.22 \times 10^{-6}$. B) Tissue enrichment analyses with MAGMA. Red dashed line indicates Bonferroni threshold, set to p=0.05/54=0.0009.

362

363 Genetic correlations of AMH levels with diseases and traits

364 From genetic correlation analysis assessing the relationship between AMH levels and 1,335 365 traits (summary statistics for those traits are found in http://www.nealelab.is/uk-biobank/), 366 three traits reflecting menopausal timing remained significant after FDR correction, all 367 displaying very high genetic correlations with AMH levels: 'Age at menopause' (r_a=0.95, se=0.21, p=8.85 x 10⁻⁶), 'Had menopause' (referring to having already undergone 368 menopause) (r_0 =-0.99, se=0.22, p=1.56 x 10⁻⁵) and 'Age started hormone-replacement 369 370 therapy (HRT)' (age for initiation of hormone replacement therapy) ($r_a=0.92$, se=0.21, 371 p=2.05 x 10⁻⁵). Additionally, we observed a range of nominally significant associations 372 (p<0.05) with traits spanning reproductive/hormonal traits (such as polyp of female genital 373 tract and female genital prolapse), metabolic traits such as inverse relationship with HbA1c

and positive correlations with neoplasms such as breast and bowel cancer. (Supplementary Figure 3 and full results and details can be found in Supplementary Table 6).



376

Supplementary Figure 3. Genetic correlation results between AMH summary statistics and publicly available summary statistics for other traits. Out of 1,335 associations, the lower section depicts significant associations after FDR correction (p-adj<0.05) and the upper section depicts nominal significant correlations (p<0.05). Dots show the estimated genetic correlation (rg) and error bars indicate 95% confidence limits. Dotted red line indicates no genetic correlation. ICD10: International Classifications of Diseases 10th Revision.

384 Phenome-wide association study

To get more insights into phenotypic manifestations of the AMH-associated variants, we performed a phenome-wide association study using the GWAS Catalog. We detected that associated variants in the six loci identified had associations across several traits, spanning from cardiovascular traits, age at menopause, estradiol levels, heel bone mineral density, breast cancer, uterine fibroids, PCOS to blood cell counts (Supplementary Table 7 and Supplementary Figure 3).

We performed a further look-up of the lead variants in the FinnGen study (data freeze 9, total n=377,277), which combines samples collected from Finnish biobanks to digital health care data. We detected that two of the lead variants had associations (p<1 x 10^{-5}) with outcomes in FinnGen, rs762643 (near *BMP4*) associated with cervical disc disorders and hernia, while rs186430430 (near *CHEK2*) associated with a variety of outcomes including diseases of the

genitourinary tract, different neoplasms (e.g. leiomyoma of uterus, neoplasms of ovary), and
 breast-cancer-related outcomes (full results can be found in Supplementary Table 8).



398

Supplementary Figure 4. River plot showing the association between lead variants (or variants in high LD with these) identified in our AMH GWAS (left column) and independent traits which show significant association results for respective variants in the GWAS Catalog (right column).

403

404 DISCUSSION

Our GWAS meta-analysis of circulating AMH measurements in 9,668 pre-menopausal
women, including 2,619 measurements from women at age 31 years old from the
NFBC1966, identified three novel association signals near *EIF4EBP1*, *BMP4* and *CHEK2*.
We also detected three previously identified signals near *TEX41*, *MCM8*, and *AMH*(Verdiesen *et al.*, 2022).

410 CHEK2 was one of the most interesting associated loci. Of note, the lead variant near CHEK2 (rs186430430, p=9.69 × 10⁻¹¹, MAF= 0.002) is in complete linkage disequilibrium 411 (r²=1) with a frameshift variant, c.1100delC (rs555607708, found in NFBC GWAS only, 412 $p=6.69 \times 10^{-05}$, OR=1.87, 95% CI= 1.37-2.55), as it is enriched in the Finnish population 413 414 (MAF=0.008) compared to other non-Finnish and non-Estonian European populations (MAF=0.002) (Tyrmi et al., 2022). Apart from being known as a moderate risk gene for 415 416 breast cancer, different GWA studies highlighted loss of function alleles in CHEK2 to be associated with firstly, PCOS (Tyrmi et al., 2021) and secondly, with ovarian ageing 417 418 (assessed as age at natural menopause) (Ruth et al., 2021). Furthermore, recent research 419 done with exome data has also identified an association between CHEK2 truncating variants 420 (excluding c.1110delC) and later age at menarche (Kentistou et al., 2023).

421 *CHEK2* encodes a checkpoint kinase 2, which induces cell cycle arrest and apoptosis in 422 response to DNA damage (Ahn *et al.*, 2004), also in oocytes with unrepaired DNA damage 423 (Ruth *et al.*, 2021). In the work from *Ruth et al.*, 2021 Chek2-/- female mice showed reduced 424 follicular atresia around reproductive senescence, increased follicular response to

gonadotrophin stimulation, and also elevated AMH levels around reproductive senescence.
 Our finding goes in line with this research and supports the hypothesis that loss of function in
 CHEK2 might result in decreased follicular atresia and higher AMH levels also in young
 premenopausal women.

429 In our general meta-analysis, we also detected previously identified associations of a 430 missense variant in MCM8 (Ruth et al., 2019; Verdiesen et al., 2022), a known DNA repair 431 gene (Park et al., 2013). This missense variant has been associated previously with 432 premature ovarian failure, infertility, age at menopause (Day et al., 2015) and cancer 433 (Michailidou et al., 2017; Griffin and Trakselis, 2019; Lutzmann et al., 2019). However, this 434 association was the weakest in NFBC66 alone. While this could support an age-specific 435 effect of the missense variant, as supported in Verdiesen et al. upon identifying a negative 436 effect direction for the cohort including adolescents versus older cohorts, this discrepancy 437 might be as well due to the variant's lower frequency in the Finnish population (MAF=0.02 438 compared to MAF=0.06 in other European populations) and a smaller sample size in the 439 NFBC1966 study. Further research including age-stratified groups with AMH levels available 440 and genetic data might inform potential age-specific effects of genetic signals.

441

442 Regarding the missense variant in the AMH gene also reported in Verdiesen et al., the 443 association between the missense variant rs10417628 in the AMH gene and AMH levels 444 remains unclear in the current analysis. A case report from 2020 suggested that this variant 445 reduces AMH detection without affecting its bioactivity (Hoyos et al., 2020). Previous GWAS 446 meta-analysis also provided inconclusive results due to inconsistent evidence from different 447 assay data. In the NFBC66 study using an automated assay (Elecsys[®] AMH Plus), the 448 missense variant showed a p-value of 0.15 (n=2,619), supporting the hypothesis of a 449 detection issue rather than an actual difference in AMH bioactivity. However, comparing 450 AMH values from different assays remains problematic, and recent evidence suggests lower 451 values in automated assays compared to Gen II and Ansh Labs assay (Moolhuijsen and 452 Visser, 2020). Further research is needed to validate the association between rs10417628 453 and AMH levels using different assays.

Colocalization analysis supports regulatory effects of GWAS variants associated with AMH with genetic variants modifying expression levels of *TEX41*, *BMP4* and *EIF4EBP1* and thus provides a refinement for the characterization of possible regulatory effects of the genetic variants on different transcripts and genes.

Interestingly, we observed high posterior probability (PP4=0.99) of colocalization between our GWAS signal and eQTL signal for the *TEX41* (Testis expressed 41) transcript ENST00000414256 in the testis, prioritising this long non-coding RNA gene for the first time in association with AMH levels based on colocalization analysis. In the same locus, *ZEB2* shows biological plausibility as a candidate gene since it plays a role as inhibitor of signal transduction in TGF-B and BMP signalling through interaction with ligand-activated SMAD proteins (Postigo *et al.*, 2003; Conidi *et al.*, 2011).

Colocalization analysis also supported the nomination of *EIF4EBP1* in the novel locus identified in chromosome 8. This gene encodes a translation repressor protein that competitively binds to eukaryotic translation initiation factor 4E (EIF4E) (Gingras *et al.*, 1999; Harris and Lawrence, 2003) and is a major substrate of mTOR and a key player in mTOR signalling pathway. Studies show that both EIF4EBP1 and EIF4E are involved in cancer development and progression where up-regulated EIF4E plays an oncogenic role in

471 carcinogenesis (Heikkinen *et al.*, 2013; Cha *et al.*, 2015). The same intergenic lead variant in
472 this locus has been associated with age at menopause, and other menopause-related traits
473 (ever had menopause and ever used hormone-replacement therapy), supporting a plausible
474 association with AMH levels.

We observed colocalization between our GWAS signal and variants modulating gene expression of *BMP4*. *BMP4* has a known regulatory role on AMH expression through activation of the SMAD proteins (Estienne *et al.*, 2015; Pierre *et al.*, 2016). Smad interacting protein 1 (also known as *ZEB2*) is one of the plausible candidate genes in chromosome 2, which would as well interact with SMAD proteins and participate in AMH regulation (Postigo *et al.*, 2003).

481 Our GWAS of AMH measurements revealed significant enrichment in renal system vascular 482 morphogenesis, glomerulus vascular morphogenesis, and glomerulus morphogenesis gene 483 set analysis. This supports the close connection between urinary and reproductive system 484 development, originating from a common embryological origin, the intermediate mesoderm. 485 Additionally, in our gene set enrichment results, we observed a nominal significance association with the gonadal mesoderm gene set ($p=4.2 \times 10^{-5}$), further supporting the 486 interconnectedness of the urinary and reproductive systems during development. We 487 488 propose that this observation may be linked to the identification of BMP4 locus associated 489 with AMH levels. The BMP4 signalling pathway is crucial during kidney development, 490 including ureteric bud outgrowth (Grinspon and Rey, 2014; Nishinakamura and Sakaguchi, 491 2014; Oxburgh et al., 2014). This observation suggests that genetic variants affecting the 492 renal system's development and function could influence AMH levels in women later in life. 493 To gain further insight, studying AMH levels in younger cohorts and conducting sex-stratified 494 analyses may be valuable in understanding the association between urogenital development 495 and AMH levels in postnatal stages.

Tissue expression analysis also identified enrichment in the pituitary gland, although this did not reach significance after multiple testing correction. This result goes in line with research from recent years showing that AMH has versatile actions in different levels of the hypothalamus-pituitary-gonadal axis (Silva and Giacobini, 2021), further supporting the developmental alterations of neuroendocrine circuits regulating fertility.

501 We identified three significant genetic correlations which align with the observations in 502 Verdiesen et al., indicating a strong positive genetic correlation between AMH and traits 503 reflecting age at menopause, suggesting shared underlying genetic risk factors and 504 supporting AMH as a proxy for ovarian reserve. We also found interesting nominal significant 505 associations, pointing towards a shared genetic background between AMH levels and breast 506 cancer, consistent with epidemiological studies (Ge et al., 2018). We hypothesise both 507 MCM8 and CHEK2 loci may play a role in this relationship and Mendelian randomisation 508 studies with independent samples could further investigate this association's direction.

509 Upon guerying the AMH GWAS lead variants and variants in high linkage disequilibrium with 510 those in other traits, we found shared significant signals amongst known epidemiological 511 associations (Homburg and Crawford, 2014; De Kat et al., 2017; Ge et al., 2018; 512 Moolhuijsen and Visser, 2020) with AMH such as PCOS, breast cancer, postmenopausal 513 status (age at menopause, estradiol levels, heel bone mineral density) and cardiovascular 514 disease. Additionally, we observed novel associations with other traits in European ancestry 515 studies, including uterine fibroids (coming from signal in MCM8) and blood cell counts 516 (coming from signals near CHEK2, which has been also associated recently with clonal hematopoiesis (Kar et al., 2022). Further epidemiological studies assessing the potential 517

causal relationships between these traits and AMH levels are warranted to better understandthe mechanisms underlying these associations.

520 Our study has several strengths, including a large sample size and inclusion of a founder 521 population, which allowed us to identify novel rare variants associated with AMH levels. 522 Furthermore, a younger cohort and equal age of measurement from 2,619 women increases 523 the variability of AMH levels and boosts the power to detect associations. We also performed 524 colocalization analysis for the first time, which provides a refinement for the characterization 525 of possible regulatory effects of the genetic variants on different transcripts and genes and 526 detect significant gene set enrichment. Our study has some limitations to consider. First, we 527 only included women of European ancestry, and our findings may not be generalizable to 528 other populations. Second, as with other reproductive phenotypes, the lack of sufficiently 529 sized datasets from relevant tissue in commonly used gene expression databases hinders a 530 more reliable assessment of the mechanisms underlying regulatory effects in reproductive 531 tissues.

In conclusion, our study expands our understanding of the genetic determinants of serum AMH levels in pre-menopausal women by identifying new loci associated with serum AMH concentration. Our results highlight the increased power of founder populations and larger sample sizes to boost the discovery of novel trait-associated variants underlying variation in AMH levels and to explore plausible genetic regulatory effects of the variants identified. Further studies are needed to validate our findings and to explore the biological mechanisms underlying the identified associations.

539

540 Acknowledgments

- 541 We want to thank the participants and investigators of the FinnGen study and the NFBC1966
- study. Part of the computations were performed in the High-Performance Computing Center
- 543 of University of Tartu.

544

545 Bibliography

- Ahn J, Urist M, Prives C. The Chk2 protein kinase. *DNA Repair (Amst)* [Internet]
 2004;3:1039–1047. DNA Repair (Amst).
- Bulik-Sullivan B, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL,
 Neale BM, Corvin A, *et al.* LD score regression distinguishes confounding from
 polygenicity in genome-wide association studies. *Nat Genet* 2015;47:291–295. Nature
 Publishing Group.
- 552 Cha YL, Li PD, Yuan LJ, Zhang MY, Zhang YJ, Rao HL, Zhang HZ, Zheng XFS, Wang HY. 553 EIF4EBP1 overexpression is associated with poor survival and disease progression in 554 patients with hepatocellular carcinoma. *PLoS One* [Internet] 2015;**10**:. PLoS One.
- Conidi A, Cazzola S, Beets K, Coddens K, Collart C, Cornelis F, Cox L, Joke D, Dobreva
 MP, Dries R, *et al.* Few Smad proteins and many Smad-interacting proteins yield
 multiple functions and action modes in TGFβ/BMP signaling in vivo. *Cytokine Growth Factor Rev* [Internet] 2011;22:287–300. Cytokine Growth Factor Rev.
- Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, Stolk L, Finucane
 HK, Sulem P, Bulik-Sullivan B, *et al.* Large-scale genomic analyses link reproductive
 aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated
 DNA repair. *Nat Genet* [Internet] 2015;**47**:1294–1303. Nat Genet.
- 563 Estienne A, Pierre A, Clemente N Di, Picard JY, Jarrier P, Mansanet C, Monniaux D, Fabre

564 565	S. Anti-Müllerian hormone regulation by the bone morphogenetic proteins in the sheep ovary: deciphering a direct regulatory pathway. <i>Endocrinology</i> [Internet] 2015; 156 :301–212. Endocrinology
566	313. Endochnology.
567	FINKeistel JS, Lee H, Karlamangia A, Nee RM, Sius PM, Burnett-Bowie SAM, Darakananda
568	K, Donano PK, Harlo SD, Prizan SH, <i>et al.</i> Antimulierian Hormone and Impending
569	Menopause in Late Reproductive Age: The Study of Women's Health Across the
570	Nation. J Clin Endocrinol Metab [Internet] 2020;105:E1862–E1871. J Clin Endocrinol
571	
572	Foley CN, Staley JR, Breen PG, Sun BB, Kirk PDW, Burgess S, Howson JMM. A fast and
573	efficient colocalization algorithm for identifying shared genetic risk factors across
574	multiple traits. Nat Commun [Internet] 2021;12:. Nat Commun.
5/5	Ge W, Clendenen T V., Afanasyeva Y, Koenig KL, Agnoli C, Brinton LA, Dorgan JF,
576	Eliassen AH, Falk RT, Hallmans G, et al. Circulating anti-Mullerian hormone and breast
577	cancer risk: A study in ten prospective cohorts. Int J cancer [Internet] 2018;142:2215-
578	2226. Int J Cancer.
579	Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment
580	to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913–963.
581	United States.
582	Griffin WC, Trakselis MA. The MCM8/9 complex: A recent recruit to the roster of helicases
583	involved in genome maintenance. DNA Repair (Amst) [Internet] 2019;76:1–10. DNA
584	Repair (Amst).
585	Grinspon RP, Rey RA. When normone defects cannot explain it: malformative disorders of
586	sex development. Birth Defects Res C Embryo Today [Internet] 2014;102:359–373.
587	Birth Defects Res C Embryo Today.
588	Harris TE, Lawrence JCJ. TOR signaling. Sci STRE 2003; 2003 :re15. United States.
589	Heikkinen T, Korpela T, Fagernolm R, Khan S, Alttomaki K, Heikkila P, Blomqvist C, Carpen
590	O, Nevanlinna H. Eukaryotic translation initiation factor 4E (eIF4E) expression is
591	associated with breast cancer tumor phenotype and predicts survival after anthracycline
592	chemotherapy treatment. Breast Cancer Res Treat [Internet] 2013;141:79–88. Breast
593	Cancer Res Treat.
594	homburg R, Clawiold G. The fole of Alvin in anovulation associated with PCOS. a
595	hypothesis. Hum Reprod [internet] 2014, 29 . 1117–1121. Hum Reprod.
590	Müllerien hermone (AMH) immuneestivitu due te e hemotureun AMH gene verient
597	rs10/17628 in a woman with classical polycystic overy syndrome (PCOS). Hum Ponrod
550	Internet 2020 35 :2204, 2202, Hum Popred
599	[Internet] 2020, 30 .2234–2302. Hum Kepfou. Kar SP, Ouiros PM, Gu M, Jiang T, Mitchell J, Jangdon P, Iver V, Barcena C, Vijavabaskar
600	MS Eabre MA et al. Conome-wide analyses of 200 453 individuals vield new insidets
602	into the causes and consequences of clonal hematonoiesis. Nat Cenet [Internet]
602	2022:54:1155-1166 Nat Genet
604	Kat AC De Monique Verschuren W. Eijkemans MIC. Broekmans E IM. Schouw VT. Van Der
605	Anti-Müllerian Hormone Trajectories Are Associated With Cardiovascular Disease in
606	Women: Results From the Doetinchem Cohort Study. Circulation [Internet]
607	2017: 135 :556–565. Circulation
608	Kent W L Sugnet CW Furey TS Roskin KM Pringle TH Zahler AM Haussler and D The
600	human genome browser at LICSC Genome Res Internet 2002: 12 :996–1006 Genome
610	Ros
611	Kentistou KA Kaisinger I.R. Stankovic S. Vaudel M. Oliveira FM de Messina A. Walters RG
612	Liu X Busch AS Helgason H <i>et al</i> Understanding the genetic complexity of puberty
613	timing across the allele frequency spectrum medRxiv [Internet] 2023: Cold Spring
614	Harbor Laboratory PressAvailable from:
615	https://www.medrxiv.org/content/early/2023/06/20/2023 06 14 23291322
616	Kerimov N Havhurst JD Peikova K Manning JR Walter P Kolberg L Samoviča M
617	Sakthivel MP. Kuzmin I. Trevanion SJ. et al. A compendium of uniformly processed
618	human gene expression and splicing quantitative trait loci. <i>Nat Genet</i> [Internet]

610	2021-53-1200-1200
620	Kurki MI Karialainen I Palta P. Sinilä TP. Kristiansson K. Donner KM. Reeve MP. Laivuori
621	H Aavikko M Kaunisto MA <i>et al</i> FinnGen provides genetic insights from a well-
622	phenotyped isolated population <i>Nature</i> [Internet] 2023 :613 :508–518 Nature
623	Lutzmann M. Bernex F. Costa de Jesus C da Hodroi D. Marty C. Plo I. Vainchenker W
624	Tosolini M. Forichon I. Bret C. et al. MCM8- and MCM9 Deficiencies Cause Lifelong
625	Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors. <i>Cell</i>
626	Ren [Internet] 2019 28 :2851-2865 e4. Cell Ren
627	Mägi R Morris AP GWAMA: software for genome-wide association meta-analysis BMC
628	Bioinformatics 2010:11:288.
629	Michailidou K. Lindström S. Dennis J. Beesley J. Hui S. Kar S. Lemacon A. Soucy P. Glubb
630	D. Rostamianfar A. <i>et al.</i> Association analysis identifies 65 new breast cancer risk loci.
631	Nature [Internet] 2017: 551 :92–94. Nature.
632	Moolhuijsen LME. Visser JA. Anti-Müllerian Hormone and Ovarian Reserve: Update on
633	Assessing Ovarian Function. J Clin Endocrinol Metab [Internet] 2020:105:. J Clin
634	Endocrinol Metab.
635	Nishinakamura R, Sakaguchi M. BMP signaling and its modifiers in kidney development.
636	Pediatr Nephrol [Internet] 2014;29:681–686. Pediatr Nephrol.
637	Nordström T, Miettunen J, Auvinen J, Ala-Mursula L, Keinänen-Kiukaanniemi S, Veijola J,
638	Järvelin M-R, Sebert S, Männikkö M. Cohort Profile: 46 years of follow-up of the
639	Northern Finland Birth Cohort 1966 (NFBC1966). Int J Epidemiol 2022;50:1786-1787j.
640	England.
641	Oxburgh L, Brown AC, Muthukrishnan SD, Fetting JL. Bone morphogenetic protein signaling
642	in nephron progenitor cells. <i>Pediatr Nephrol</i> [Internet] 2014; 29 :531–536. Pediatr
643	Nephrol.
644	Park J, Long DT, Lee KY, Abbas T, Shibata E, Negishi M, Luo Y, Schimenti JC, Gambus A,
645	Walter JC, et al. The MCM8-MCM9 complex promotes RAD51 recruitment at DNA
646	damage sites to facilitate homologous recombination. Mol Cell Biol [Internet]
647	2013; 33 :1632–1644. Mol Cell Biol.
648	Pierre A, Estienne A, Racine C, Picard JY, Fanchin R, Lahoz B, Alabart JL, Folch J, Jarrier
649	P, Fabre S, et al. The Bone Morphogenetic Protein 15 Up-Regulates the Anti-Müllerian
650	Hormone Receptor Expression in Granulosa Cells. J Clin Endocrinol Metab [Internet]
651	2016; 101 :2602–2611. J Clin Endocrinol Metab.
652	Piltonen II, Komsi E, Morin-Papunen LC, Korhonen E, Franks S, Järvelin M-R, Arffman RK,
653	Ollila M-M. AMH as part of the diagnostic PCOS workup in large epidemiological
654	studies. Eur J Endocrinol 2023;188:547-554. England.
655	Postigo AA, Depp JL, Taylor JJ, Kroll KL. Regulation of Smad signaling through a differential
656	recruitment of coactivators and corepressors by ZEB proteins. <i>EMBO J</i> [Internet]
657 CE0	2003; 22 :2433-2462. EMBO J. Buth KS, Day EB, Huggain J, Martínaz Marchal A, Aikan CE, Azad A, Thompson DJ.
658	Ruin KS, Day FR, Hussain J, Maninez-Marchai A, Aiken CE, Azad A, Thompson DJ,
659	KIODIOCHOVA L, ADE H, TATTY-AOKINS JL, <i>et al.</i> Genetic Insights into biological
660	Noturo
662	Puth KS Soares ALC Borges MC Eliassen AH Hankinson SE Jones ME Kraft P Nichols
663	HB Sandler DP Schoemaker MI et al Genome-wide association study of anti-
664	Müllerian hormone levels in pre-menonausal women of late reproductive are and
665	relationship with genetic determinants of reproductive lifespan. Hum Mol Genet
666	[Internet] 2019: 28 :1392–1401. Hum Mol Genet
667	Schub-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA, Genetic
668	markers of ovarian follicle number and menopause in women of multiple ethnicities
669	Hum Genet [Internet] 2012: 131 :1709–1724. Hum Genet
670	Silva MSB. Giacobini P. New insights into anti-Müllerian hormone role in the hypothalamic-
671	pituitary-gonadal axis and neuroendocrine development. <i>Cell Mol Life Sci</i> [Internet]
672	2021; 78 :. Cell Mol Life Sci.
673	Tyrmi JS, Arffman RK, Pujol-Gualdo N, Kurra V, Morin-Papunen L, Sliz E, FinnGen, Team

- EBR, Piltonen TT, Laisk T, et al. Leveraging Northern European population history; novel low frequency variants for polycystic ovary syndrome. medRxiv [Internet] 675 2021:2021.05.20.21257510Available from: 676 http://medrxiv.org/content/early/2021/05/24/2021.05.20.21257510.abstract. 677 Tyrmi JS, Arffman RK, Pujol-Gualdo N, Kurra V, Morin-Papunen L, Sliz E, Piltonen TT, Laisk 678 T, Kettunen J, Laivuori H. Leveraging Northern European population history: novel low-679 680 frequency variants for polycystic ovary syndrome. Hum Reprod [Internet] 2022;37:352-681 365. Hum Reprod. 682 Verdiesen RMG, Schouw YT Van Der, Gils CH Van, Verschuren WMM, Broekmans FJM, 683 Borges MC, Gonçalves Soares AL, Lawlor DA, Eliassen AH, Kraft P, et al. Genome-684 wide association study meta-analysis identifies three novel loci for circulating anti-685 Müllerian hormone levels in women. Hum Reprod [Internet] 2022;37:1069–1082. 686 Oxford University Press. Watanabe K, Taskesen E, Bochoven A van, Posthuma D. Functional mapping and 687 688 annotation of genetic associations with FUMA. Nat Commun 2017;8:1826. 689 Weenen C, Laven JSE, Bergh ARM von, Cranfield M, Groome NP, Visser JA, Kramer P,
- 690 Fauser BCJM, Themmen APN. Anti-Müllerian hormone expression pattern in the
- 691 human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum 692 Reprod [Internet] 2004;10:77-83. Mol Hum Reprod.
- 693

















Gene set enrichment with MAGMA



ICD10: N84 Polyp of female genital tract ICD10: N81 Female genital prolapse Ever used hormone-replacement therapy (HRT) Age of primiparous women at birth of child Age first had sexual intercourse Urea Pain type experienced in last month: Headache ICD10: M51 Other intervertebral disk disorders ICD10: E04 Other non-toxic goitre Heel bone mineral density (BMD) Worrier / anxious feelings Age at first episode of depression Triglycerides Treatment: lisinopril+hydrochlorothiazide Glycated haemoglobin (HbA1c) Arm fat-free mass (left) Malignant neoplasm of breast Illnesses of mother: Bowel cancer Had menopause Age started hormone-replacement therapy (HRT) Age at menopause (last menstrual period)

rs13009019 (<i>TEX41/ZEB2</i>)	Systolic blood pressure
	Arterial stiffness
TEV 41/7ED2)	Coronary artery disease
$157575637 (1 \ge 447/2 \ge 22)$	Triglyceride levels
	Aortic valve stenosis
rs10093345 (<i>EIF4EBP1</i>)	Age at menopause
rs762643 (<i>BMP4</i>)	Detectable estradiol levels
	Bone stiffness index
	Myopia (age of diagnosis)
	Heel bone mineral density
$r_{c16001615}$ (MCM8)	Uterine fibroids
1310991013 (INCINO)	Heavy menstrual bleeding
	Menarche and menopause (age at onset)
	Uterine leiomyoma or ER positive breast cancer (pleiotropy)
rs145598156 (CHEK2)	Mean platelet volume
	Lymphocyte count
	Plateletcrit
	Ovarian cyst
re186430430 (CHEK2)	Prostate cancer
13180430430 (CHEKZ)	Breast cancer
	Neutrophil count
	White blood cell count
rs62236881 (CHEK2)	Polycystic ovary syndrome (adjusted for age)





Blood cell counts

Cancer

Cardiovascular disease

Menopause related trait

Reproductive traits